The chemotherapy induced peripheral neuropathy treatment market is segmented by drug class into neurotransmitter-based therapy and other drug classes. The neurotransmitter based therapy market was the largest segment of the chemotherapy induced peripheral neuropathy treatment market segmented by drug class, accounting for 80.64% or $1.33 billion of the total in 2024. Going forward, the other drug classes segment is expected to be the fastest growing segment in the chemotherapy induced peripheral neuropathy treatment market segmented by drug class, at a CAGR of 9.07% during 2024-2029.
The chemotherapy induced peripheral neuropathy treatment market is segmented by treatment into medication, therapy and other treatments. The medication market was the largest segment of the chemotherapy induced peripheral neuropathy treatment market segmented by treatment, accounting for 84.82% or $1.39 billion of the total in 2024. Going forward, the therapy segment is expected to be the fastest growing segment in the chemotherapy induced peripheral neuropathy treatment market segmented by treatment, at a CAGR of 6.65% during 2024-2029.
The chemotherapy induced peripheral neuropathy treatment market is segmented by drug type into branded and generic. The generic market was the largest segment of the chemotherapy induced peripheral neuropathy treatment market segmented by drug type, accounting for 93.85% or $ 1.54 billion of the total in 2024. Going forward, the branded segment is expected to be the fastest growing segment in the chemotherapy induced peripheral neuropathy treatment market segmented by drug type, at a CAGR of 7.05% during 2024-2029.
The chemotherapy induced peripheral neuropathy treatment market is segmented by distribution channel into hospital pharmacy, retail pharmacy, online pharmacies and other distribution channels. The hospital pharmacy market was the largest segment of the chemotherapy induced peripheral neuropathy treatment market segmented by distribution channel, accounting for 53.18% or $ 877.47 million of the total in 2024. Going forward, the online pharmacies segment is expected to be the fastest growing segment in the chemotherapy induced peripheral neuropathy treatment market segmented by distribution channel, at a CAGR of 6.69% during 2024-2029.
The chemotherapy induced peripheral neuropathy treatment market is segmented by end-user into hospitals, research institutes and specialty clinic. The hospitals market was the largest segment of the chemotherapy induced peripheral neuropathy treatment market segmented by end-user, accounting for 62.67% or $1.03 billion of the total in 2024. Going forward, the specialty clinics segment is expected to be the fastest growing segment in the chemotherapy induced peripheral neuropathy treatment market segmented by end-user, at a CAGR of 6.40% during 2024-2029.
North America was the largest region in the chemotherapy induced peripheral neuropathy treatment market, accounting for 43.46% or $717.11 million of the total in 2024. It was followed by Asia Pacific, Western Europe and then the other regions. Going forward, the fastest-growing regions in the chemotherapy induced peripheral neuropathy treatment market will be Asia Pacific and Middle East where growth will be at CAGRs of 10.44% and 8.08% respectively. These will be followed by Africa and Eastern Europe where the markets are expected to grow at CAGRs of 7.82% and 6.90% respectively.
The global chemotherapy induced peripheral neuropathy treatment market is fairly concentrated, with large players operating in the market. The top 10 competitors in the market made up 33.13% of the total market in 2023. Teva Pharmaceuticals was the largest competitor with a 4.93% share of the market, followed by Aurobindo Pharma Limited with 4.45%, Viatris Inc. (Mylan) with 3.84%, Sun Pharmaceutical Industries Ltd., with 3.66%, Zydus Lifesciences Limited (formerly Cadila Healthcare Limited), with 3.30%, Lupin Limited with 3.01%, Sandoz Group AG with 2.96%, Torrent Pharmaceuticals Ltd with 2.63%, Alkem Laboratories Limited with 2.47%. and Dr Reddys Laboratories Ltd. with 1.88%.
This report describes and explains the chemotherapy induced peripheral neuropathy treatment market and covers 2019-2024, termed the historic period, and 2024-2029, 2034F termed the forecast period. The report evaluates the market across each region and for the major economies within each region.
The global chemotherapy induced peripheral neuropathy treatment market reached a value of nearly $1.65 billion in 2024, having grown at a compound annual growth rate (CAGR) of 5.24% since 2019. The market is expected to grow from $1.65 billion in 2024 to $2.22 billion in 2029 at a rate of 6.17%. The market is then expected to grow at a CAGR of 5.81% from 2029 and reach $2.95 billion in 2034.
Growth in the historic period resulted from increasing prevalence of cancer, rising number of clinical trials and rising adoption of pain management therapies. Factors that negatively affected growth in the historic period were the high treatment costs and healthcare reimbursement challenges.
Going forward, supportive government initiatives and funding, expansion of chemotherapy usage, growing awareness among oncologists and patients and improved cancer survival rates support will drive growth. Factor that could hinder the growth of the chemotherapy induced peripheral neuropathy treatment market in the future include were limited FDA-approved drugs impact of trade war and tariff and regulatory uncertainty.
The top opportunities in the chemotherapy induced peripheral neuropathy treatment market segmented by drug class will arise in the neurotransmitter based therapy segment, which will gain $1.75 billion of global annual sales by 2029. The top opportunities in the chemotherapy induced peripheral neuropathy treatment market segmented by treatment will arise in the medication segment, which will gain $1.88 billion of global annual sales by 2029. The top opportunities in the chemotherapy induced peripheral neuropathy treatment market segmented by drug type will arise in the generic segment, which will gain $2.08 billion of global annual sales by 2029. The top opportunities in the chemotherapy induced peripheral neuropathy treatment market segmented by distribution channel will arise in the hospital pharmacy segment, which will gain $1.16 billion of global annual sales by 2029. The top opportunities in the chemotherapy induced peripheral neuropathy treatment market segmented by end-user will arise in the hospitals segment, which will gain $1.37 billion of global annual sales by 2029. The chemotherapy induced peripheral neuropathy treatment market size will gain the most in the USA at $104.33 million.
Market-trend-based strategies for the chemotherapy induced peripheral neuropathy treatment market include collaborative research enhances understanding of chemotherapy-induced peripheral neuropathy, advances in selective FABP5 inhibitors for chemotherapy-induced peripheral neuropathy and strategic funding advances neuroprotective therapies for chemotherapy-related nerve damage.
To take advantage of the opportunities, the analyst recommends the chemotherapy induced peripheral neuropathy treatment market companies to focus on leveraging regulatory advances to accelerate CIPN treatment development, focus on strategic investment to advance novel CIPN therapies, focus on expanding in the fastest-growing CIPN treatment segment, focus on expanding medication segment to drive CIPN market growth, focus on expanding branded drug segment to capture high growth in CIPN market, expand in emerging markets, focus on strategic collaborations to accelerate innovation and market growth, focus on competitive and value-based pricing strategies, focus on educational and multichannel promotion, focus on collaboration and KOL engagement, focus on expanding online pharmacy segment for CIPN treatment distribution and focus on specialty clinics to capture high growth in CIPN treatment market.
This product will be delivered within 3-5 business days.
The chemotherapy induced peripheral neuropathy treatment market is segmented by treatment into medication, therapy and other treatments. The medication market was the largest segment of the chemotherapy induced peripheral neuropathy treatment market segmented by treatment, accounting for 84.82% or $1.39 billion of the total in 2024. Going forward, the therapy segment is expected to be the fastest growing segment in the chemotherapy induced peripheral neuropathy treatment market segmented by treatment, at a CAGR of 6.65% during 2024-2029.
The chemotherapy induced peripheral neuropathy treatment market is segmented by drug type into branded and generic. The generic market was the largest segment of the chemotherapy induced peripheral neuropathy treatment market segmented by drug type, accounting for 93.85% or $ 1.54 billion of the total in 2024. Going forward, the branded segment is expected to be the fastest growing segment in the chemotherapy induced peripheral neuropathy treatment market segmented by drug type, at a CAGR of 7.05% during 2024-2029.
The chemotherapy induced peripheral neuropathy treatment market is segmented by distribution channel into hospital pharmacy, retail pharmacy, online pharmacies and other distribution channels. The hospital pharmacy market was the largest segment of the chemotherapy induced peripheral neuropathy treatment market segmented by distribution channel, accounting for 53.18% or $ 877.47 million of the total in 2024. Going forward, the online pharmacies segment is expected to be the fastest growing segment in the chemotherapy induced peripheral neuropathy treatment market segmented by distribution channel, at a CAGR of 6.69% during 2024-2029.
The chemotherapy induced peripheral neuropathy treatment market is segmented by end-user into hospitals, research institutes and specialty clinic. The hospitals market was the largest segment of the chemotherapy induced peripheral neuropathy treatment market segmented by end-user, accounting for 62.67% or $1.03 billion of the total in 2024. Going forward, the specialty clinics segment is expected to be the fastest growing segment in the chemotherapy induced peripheral neuropathy treatment market segmented by end-user, at a CAGR of 6.40% during 2024-2029.
North America was the largest region in the chemotherapy induced peripheral neuropathy treatment market, accounting for 43.46% or $717.11 million of the total in 2024. It was followed by Asia Pacific, Western Europe and then the other regions. Going forward, the fastest-growing regions in the chemotherapy induced peripheral neuropathy treatment market will be Asia Pacific and Middle East where growth will be at CAGRs of 10.44% and 8.08% respectively. These will be followed by Africa and Eastern Europe where the markets are expected to grow at CAGRs of 7.82% and 6.90% respectively.
The global chemotherapy induced peripheral neuropathy treatment market is fairly concentrated, with large players operating in the market. The top 10 competitors in the market made up 33.13% of the total market in 2023. Teva Pharmaceuticals was the largest competitor with a 4.93% share of the market, followed by Aurobindo Pharma Limited with 4.45%, Viatris Inc. (Mylan) with 3.84%, Sun Pharmaceutical Industries Ltd., with 3.66%, Zydus Lifesciences Limited (formerly Cadila Healthcare Limited), with 3.30%, Lupin Limited with 3.01%, Sandoz Group AG with 2.96%, Torrent Pharmaceuticals Ltd with 2.63%, Alkem Laboratories Limited with 2.47%. and Dr Reddys Laboratories Ltd. with 1.88%.
This report describes and explains the chemotherapy induced peripheral neuropathy treatment market and covers 2019-2024, termed the historic period, and 2024-2029, 2034F termed the forecast period. The report evaluates the market across each region and for the major economies within each region.
The global chemotherapy induced peripheral neuropathy treatment market reached a value of nearly $1.65 billion in 2024, having grown at a compound annual growth rate (CAGR) of 5.24% since 2019. The market is expected to grow from $1.65 billion in 2024 to $2.22 billion in 2029 at a rate of 6.17%. The market is then expected to grow at a CAGR of 5.81% from 2029 and reach $2.95 billion in 2034.
Growth in the historic period resulted from increasing prevalence of cancer, rising number of clinical trials and rising adoption of pain management therapies. Factors that negatively affected growth in the historic period were the high treatment costs and healthcare reimbursement challenges.
Going forward, supportive government initiatives and funding, expansion of chemotherapy usage, growing awareness among oncologists and patients and improved cancer survival rates support will drive growth. Factor that could hinder the growth of the chemotherapy induced peripheral neuropathy treatment market in the future include were limited FDA-approved drugs impact of trade war and tariff and regulatory uncertainty.
The top opportunities in the chemotherapy induced peripheral neuropathy treatment market segmented by drug class will arise in the neurotransmitter based therapy segment, which will gain $1.75 billion of global annual sales by 2029. The top opportunities in the chemotherapy induced peripheral neuropathy treatment market segmented by treatment will arise in the medication segment, which will gain $1.88 billion of global annual sales by 2029. The top opportunities in the chemotherapy induced peripheral neuropathy treatment market segmented by drug type will arise in the generic segment, which will gain $2.08 billion of global annual sales by 2029. The top opportunities in the chemotherapy induced peripheral neuropathy treatment market segmented by distribution channel will arise in the hospital pharmacy segment, which will gain $1.16 billion of global annual sales by 2029. The top opportunities in the chemotherapy induced peripheral neuropathy treatment market segmented by end-user will arise in the hospitals segment, which will gain $1.37 billion of global annual sales by 2029. The chemotherapy induced peripheral neuropathy treatment market size will gain the most in the USA at $104.33 million.
Market-trend-based strategies for the chemotherapy induced peripheral neuropathy treatment market include collaborative research enhances understanding of chemotherapy-induced peripheral neuropathy, advances in selective FABP5 inhibitors for chemotherapy-induced peripheral neuropathy and strategic funding advances neuroprotective therapies for chemotherapy-related nerve damage.
To take advantage of the opportunities, the analyst recommends the chemotherapy induced peripheral neuropathy treatment market companies to focus on leveraging regulatory advances to accelerate CIPN treatment development, focus on strategic investment to advance novel CIPN therapies, focus on expanding in the fastest-growing CIPN treatment segment, focus on expanding medication segment to drive CIPN market growth, focus on expanding branded drug segment to capture high growth in CIPN market, expand in emerging markets, focus on strategic collaborations to accelerate innovation and market growth, focus on competitive and value-based pricing strategies, focus on educational and multichannel promotion, focus on collaboration and KOL engagement, focus on expanding online pharmacy segment for CIPN treatment distribution and focus on specialty clinics to capture high growth in CIPN treatment market.
This product will be delivered within 3-5 business days.
Table of Contents
1 Executive Summary
6 Market Characteristics
7 Major Market Trends
8 Global Chemotherapy Induced Peripheral Neuropathy Treatment Growth Analysis And Strategic Analysis Framework
9 Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Segmentation
10 Chemotherapy Induced Peripheral Neuropathy Treatment Market, Regional and Country Analysis
11 Asia-Pacific Market
12 Western Europe Market
13 Eastern Europe Market
14 North America Market
15 South America Market
16 Middle East Market
17 Africa Market
18 Competitive Landscape And Company Profiles
19 Other Major And Innovative Companies
22 Key Mergers And Acquisitions
23 Recent Developments In The Chemotherapy Induced Peripheral Neuropathy Treatment Market
24 Opportunities And Strategies
25 Chemotherapy Induced Peripheral Neuropathy Treatment Market, Conclusions And Recommendations
26 Appendix
Executive Summary
Chemotherapy Induced Peripheral Neuropathy Treatment Global Market Opportunities And Strategies To 2034 provides the strategists; marketers and senior management with the critical information they need to assess the global chemotherapy induced peripheral neuropathy treatment market as it emerges from the COVID-19 shut down.Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Understand how the market is being affected by the coronavirus and how it is likely to emerge and grow as the impact of the virus abates.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market research findings.
- Benchmark performance against key competitors.
- Utilize the relationships between key data sets for superior strategizing.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis.
Description
Where is the largest and fastest-growing market for chemotherapy induced peripheral neuropathy treatment? How does the market relate to the overall economy; demography and other similar markets? What forces will shape the market going forward? The chemotherapy induced peripheral neuropathy treatment market global report answers all these questions and many more.The report covers market characteristics; size and growth; segmentation; regional and country breakdowns; competitive landscape; market shares; trends and strategies for this market. It traces the market’s history and forecasts market growth by geography. It places the market within the context of the wider chemotherapy induced peripheral neuropathy treatment market; and compares it with other markets.
The report covers the following chapters
- Introduction and Market Characteristics- Brief introduction to the segmentations covered in the market, definitions and explanations about the segment by drug class, by treatment, by drug type, by distribution channel and by end-user.
- Key Trends- Highlights the major trends shaping the global market. This section also highlights likely future developments in the market.
- Growth Analysis And Strategic Analysis Framework- Analysis on PESTEL, end use industries, market growth rate, global historic (2019-2024) and forecast (2024-2029, 2034F) market values and drivers and restraints that support and control the growth of the market in the historic and forecast periods, forecast growth contributors and total addressable market (TAM).
- Regional And Country Analysis- Historic (2019-2024) and forecast (2024-2029, 2034F) market values and growth and market share comparison by region and country.
- Market Segmentation- Contains the market values (2019-2024) (2024-2029, 2034F) and analysis for each segment by drug class, by treatment, by drug type, by distribution channel and by end-user in the market. Historic (2019-2024) and forecast (2024-2029) and (2029-2034) market values and growth and market share comparison by region market.
- Regional Market Size and Growth- Regional market size (2024), historic (2019-2024) and forecast (2024-2029, 2034F) market values and growth and market share comparison of countries within the region. This report includes information on all the regions Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa and major countries within each region.
- Competitive Landscape- Details on the competitive landscape of the market, estimated market shares and company profiles of the leading players.
- Other Major And Innovative Companies- Details on the company profiles of other major and innovative companies in the market.
- Competitive Benchmarking- Briefs on the financials comparison between major players in the market.
- Competitive Dashboard- Briefs on competitive dashboard of major players.
- Key Mergers and Acquisitions- Information on recent mergers and acquisitions in the market is covered in the report.This section gives key financial details of mergers and acquisitions which have shaped the market in recent years.
- Recent Developments- Information on recent developments in the market covered in the report.
- Market Opportunities And Strategies- Describes market opportunities and strategies based on findings of the research, with information on growth opportunities across countries, segments and strategies to be followed in those markets.
- Conclusions And Recommendations- This section includes recommendations for chemotherapy induced peripheral neuropathy treatment providers in terms of product/service offerings geographic expansion, marketing strategies and target groups.
- Appendix- This section includes details on the NAICS codes covered, abbreviations and currencies codes used in this report.
Markets Covered:
1) By Drug Class: Neurotransmitter-Based Therapy; Other Drug Classes2) By Treatment: Medication; Physical Therapy; Other Treatments
3) By Drug Type: Branded; Generic
4) By Distribution Channel: Hospital Pharmacy; Retail Pharmacy; Online Pharmacies; Other Distribution Channels
5) By End User: Hospitals; Research Institutes; Specialty Clinics
Key Companies Profiled: Teva Pharmaceuticals; Aurobindo Pharma Limited; Viatris Inc. (Mylan); Sun Pharmaceutical Industries Ltd.; Zydus Lifesciences Limited (formerly Cadila Healthcare Limited)
Countries: China; Australia; India; Indonesia; Japan; South Korea; USA; Canada; Brazil; France; Germany; UK; Italy; Spain; Russia
Regions:Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets; GDP proportions; expenditure per capita; chemotherapy induced peripheral neuropathy treatment indicators comparison.
Data Segmentation: Country and regional historic and forecast data; market share of competitors; market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Companies Mentioned
- Teva Pharmaceuticals
- Aurobindo Pharma Limited
- Viatris Inc. (Mylan)
- Sun Pharmaceutical Industries Ltd.
- Zydus Lifesciences Limited (formerly Cadila Healthcare Limited)
- Lupin Limited
- Sandoz Group AG
- Torrent Pharmaceuticals Ltd
- Alkem Laboratories Limited
- Dr Reddys Laboratories Ltd.
- Lotus
- Adalvo
- Veloxis Pharmaceuticals
- Asahi Kasei Pharma
- 3E-Regenacy Pharmaceuticals Co., Ltd. (BC Regenacy)
- 3E Bioventures
- Aptinyx
- Grünenthal GmbH
- AlgoTherapeutix
- Paxman
- Sanofi SA
- Abbott Laboratories
- Metys Pharmaceuticals AG
- Gedeon Richter
- KRKA
- Polpharma
- Zentiva
- MediciNova, Inc.
- Esteve
- WEX Pharmaceuticals Inc.
- Apollo Endosurgery, Inc.
- MAKScientific LLC
- Sova Health
- Kineta Inc.
- Aptinyx Inc.
- WinSanTor
- Alexion Pharmaceuticals, Inc.
- Acorda Therapeutics, Inc.
- Incyte Corporation
- Amneal Pharmaceuticals
- Amgen Inc.
- Immunity Pharma
- Bristol Myers Squibb
- Eli Lilly and Company
- Lexicon Pharmaceuticals, Inc.
- American Academy of Neurology (AAN)
- Artelo Biosciences, Inc.
- Neuropathix, Inc.
- Jazz Pharmaceuticals, Inc.
- Aphios Corporation
- Eurofarma
- Novartis
- Biodexa Pharmaceuticals PLC
- Roche Holding AG
- Relief Therapeutics
- Novaremed AG
- Takeda Pharmaceutical Company
- Pfizer
- Sanofi
- Boston Scientific
- Ain Shams University Specialized Hospital (ASUSH)
- National Hospital Abuja
- Eurofins Scientific
- Quality Chemical Industries Limited
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 326 |
| Published | September 2025 |
| Forecast Period | 2024 - 2034 |
| Estimated Market Value ( USD | $ 1.65 Billion |
| Forecasted Market Value ( USD | $ 2.95 Billion |
| Compound Annual Growth Rate | 6.0% |
| Regions Covered | Global |
| No. of Companies Mentioned | 64 |
